Miransertib is an Orally Active Akt Inhibitor for Cancer and Infection Research
In almost half of hepatocellular carcinoma (HCC) cases, the Akt pathway is activated. Miransertib is a highly selective, orally active, pan-Akt inhibitor. Miransertib target all three Akt isoforms by blocking…